TransThera Sciences

TransThera Sciences, based in Nanjing, is the Chinese biotechnology company running the first phase 3 trial of a next-generation FGFR inhibitor, tinengotinib, for bile duct cancer that has stopped responding to first-generation FGFR drugs. Tinengotinib, also known as TT-00420, is a multi-kinase inhibitor potent against the FGFR2 kinase-domain mutations that drive acquired resistance, and the FIRST-308 phase 3 trial, which compares it with physician's choice chemotherapy in FGFR-altered, FGFR-inhibitor-refractory cholangiocarcinoma, dosed its first US patient in 2025. OnCo links it to biliary tract cancer and to the tinengotinib drug record. Whether a resistance-directed FGFR inhibitor can beat chemotherapy in a population that has already progressed on targeted therapy is the question the trial will answer. Tinengotinib has its own page.